HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique

dc.contributor.authorRupérez, María
dc.contributor.authorNoguera Julian, Marc
dc.contributor.authorGonzález, Raquel
dc.contributor.authorMaculuve, Sónia Amós
dc.contributor.authorBellido, Rocío
dc.contributor.authorVala, Anifa
dc.contributor.authorRodríguez, Cristina
dc.contributor.authorSevene, Esperança Júlia Pires
dc.contributor.authorParedes, Roger
dc.contributor.authorMenéndez, Clara
dc.date.accessioned2018-06-05T07:22:15Z
dc.date.available2018-06-05T07:22:15Z
dc.date.issued2018
dc.date.updated2018-05-23T17:59:57Z
dc.description.abstractBACKGROUND: Few data on HIV resistance in pregnancy are available from Mozambique, one of the countries with the highest HIV toll worldwide. Understanding the patterns of HIV drug resistance in pregnant women might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care. OBJECTIVES: To describe the frequency and characteristics of HIV drug resistance mutations (HIVDRM) in pregnant women with virological failure at delivery, despite pMTCT or antiretroviral therapy (ART). METHODS: Samples from HIV-infected pregnant women from a rural area in southern Mozambique were analysed. Only women with HIV-1 RNA >400c/mL at delivery were included in the analysis. HIVDRM were determined using MiSeq(R) (detection threshold 1%) at the first antenatal care (ANC) visit and at the time of delivery. RESULTS: Ninety and 60 samples were available at the first ANC visit and delivery, respectively. At first ANC, 97% of the women had HIV-1 RNA>400c/mL, 39% had CD4+ counts <350 c/mm3 and 30% were previously not on ART. Thirteen women (14%) had at least one HIVDRM of whom 70% were not on previous ART. Eight women (13%) had at least one HIVDRM at delivery. Out of 37 women with data available from the two time points, 8 (21%) developed at least one new HIVDRM during pMTCT or ART. Twenty seven per cent (53/191), 32% (44/138) and 100% (5/5) of the mutations that were present at enrolment, delivery and that emerged during pregnancy, respectively, were minority mutations (frequency <20%). CONCLUSIONS: Even with ultrasensitive HIV-1 genotyping, less than 20% of women with detectable viremia at delivery had HIVDRM before initiating pMTCT or ART. This suggests that factors other than pre-existing resistance, such as lack of adherence or interruptions of the ANC chain, are also relevant to explain lack of virological suppression at the time of delivery in women receiving antiretrovirals drugs during pregnancy.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1932-6203
dc.identifier.pmid29742132
dc.identifier.urihttps://hdl.handle.net/2445/122779
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0196451
dc.relation.ispartofPLoS One, 2018, vol. 13, num. 5, p. e0196451
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0196451
dc.rightscc by (c) Rupérez et a, 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationVIH (Virus)
dc.subject.classificationEmbarassades
dc.subject.classificationMoçambic
dc.subject.otherHIV (Viruses)
dc.subject.otherPregnant women
dc.subject.otherMozambique
dc.titleHIV drug resistance patterns in pregnant women using next generation sequence in Mozambique
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
ruperez2018_3043.pdf
Mida:
676.53 KB
Format:
Adobe Portable Document Format